{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:28:06Z","timestamp":1755221286613,"version":"3.43.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118311","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T19:18:01Z","timestamp":1751656681000},"page":"118311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting enhancer of zeste homolog 2: A novel therapeutic approach for head and neck cancer"],"prefix":"10.1016","volume":"189","author":[{"given":"Sarah Adriana","family":"Scuderi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cucinotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Basilotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Mannino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Campolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2025.118311_bib1","article-title":"Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma","volume":"11","author":"Barsouk","year":"2023","journal-title":"Med Sci. (Basel)"},{"issue":"8","key":"10.1016\/j.biopha.2025.118311_bib2","article-title":"EZH2 inhibition to counteract oral cancer progression through Wnt\/beta-catenin pathway modulation","volume":"17","author":"Campolo","year":"2024","journal-title":"Pharm. (Basel)"},{"issue":"10","key":"10.1016\/j.biopha.2025.118311_bib3","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00221-023-06693-8","article-title":"Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway","volume":"241","author":"Zhao","year":"2023","journal-title":"Exp. Brain Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12920-023-01594-9","article-title":"Analysis on EZH2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinoma","volume":"16","author":"Zhao","year":"2023","journal-title":"BMC Med Genom."},{"issue":"5","key":"10.1016\/j.biopha.2025.118311_bib5","first-page":"1165","article-title":"Targeting of EZH2 inhibits epithelial\u2011mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3\/VEGFR2 axis","volume":"55","author":"Zhao","year":"2019","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.biopha.2025.118311_bib6","article-title":"PRC2, chromatin regulation, and human disease: insights from molecular structure and function","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-017-0547-3","article-title":"The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter","volume":"11","author":"Gan","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41065-023-00280-1","article-title":"EZH2 regulates pancreatic cancer cells through E2F1, GLI1, CDK3, and Mcm4","volume":"160","author":"Li","year":"2023","journal-title":"Hereditas"},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41392-020-00252-1","article-title":"The role of histone methylation in the development of digestive cancers: a potential direction for cancer management","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2025.118311_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114313","article-title":"The pharmacological and biological importance of EZH2 signaling in lung cancer","volume":"160","author":"Entezari","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"12","key":"10.1016\/j.biopha.2025.118311_bib12","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.18632\/oncotarget.1503","article-title":"The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer","volume":"4","author":"Li","year":"2013","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.biopha.2025.118311_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118311_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark. Res"},{"issue":"2","key":"10.1016\/j.biopha.2025.118311_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.gene.2014.01.006","article-title":"Role of EZH2 in oral squamous cell carcinoma carcinogenesis","volume":"537","author":"Zhao","year":"2014","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40463-016-0168-9","article-title":"Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer","volume":"45","author":"Idris","year":"2016","journal-title":"J. Otolaryngol. Head. Neck Surg."},{"issue":"47","key":"10.1016\/j.biopha.2025.118311_bib17","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1038\/onc.2017.262","article-title":"EZH2-mediated upregulation of ROS1 oncogene promotes oral cancer metastasis","volume":"36","author":"Shih","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13072-022-00439-6","article-title":"Evolutionary adaptation of the Polycomb repressive complex 2","volume":"15","author":"Fischer","year":"2022","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","article-title":"Molecular mechanisms directing PRC2 recruitment and H3K27 methylation","volume":"74","author":"Laugesen","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2025.118311_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106159","article-title":"Focus on the classical and non-classical functions of EZH2: guide the development of inhibitors and degraders","volume":"178","author":"Zhang","year":"2022","journal-title":"Pharm. Res"},{"issue":"5","key":"10.1016\/j.biopha.2025.118311_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ni.3125","article-title":"The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin","volume":"16","author":"Gunawan","year":"2015","journal-title":"Nat. Immunol."},{"issue":"6113","key":"10.1016\/j.biopha.2025.118311_bib22","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1227604","article-title":"EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent","volume":"338","author":"Xu","year":"2012","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.biopha.2025.118311_bib23","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.biopha.2025.118311_bib24","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/cas.14840","article-title":"The noncanonical role of EZH2 in cancer","volume":"112","author":"Huang","year":"2021","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118311_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/aps.2013.161","article-title":"EZH2: biology, disease, and structure-based drug discovery","volume":"35","author":"Tan","year":"2014","journal-title":"Acta Pharm. Sin."},{"issue":"5","key":"10.1016\/j.biopha.2025.118311_bib26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.molcel.2011.08.011","article-title":"Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers","volume":"43","author":"Lee","year":"2011","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib27","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/s41467-022-30105-0","article-title":"EZH2 engages TGFbeta signaling to promote breast cancer bone metastasis via integrin beta1-FAK activation","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2025.118311_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone methyltransferase EZH2: a therapeutic target for ovarian cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.118311_bib29","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.21873\/anticanres.16252","article-title":"Validation of EZH2 inhibitor efficiency in anaplastic thyroid carcinoma cell lines","volume":"43","author":"Nakayama","year":"2023","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2025.118311_bib30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/onc.2011.254","article-title":"EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1\/HDAC2 and Snail to inhibit E-cadherin","volume":"31","author":"Tong","year":"2012","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib31","doi-asserted-by":"crossref","first-page":"18290","DOI":"10.1038\/s41598-022-23253-2","article-title":"EZH2 regulates oncomiR-200c and EMT markers in esophageal squamous cell carcinomas","volume":"12","author":"Nourmohammadi","year":"2022","journal-title":"Sci. Rep."},{"issue":"29","key":"10.1016\/j.biopha.2025.118311_bib32","doi-asserted-by":"crossref","first-page":"27427","DOI":"10.18632\/oncotarget.4861","article-title":"The positive feedback between Snail and DAB2IP regulates EMT, invasion and metastasis in colorectal cancer","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.biopha.2025.118311_bib33","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.7150\/jca.26275","article-title":"EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis","volume":"9","author":"Sun","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2025.118311_bib34","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/ncomms7051","article-title":"The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors","volume":"6","author":"Zingg","year":"2015","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.biopha.2025.118311_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213915","article-title":"GSK343, an inhibitor of enhancer of zeste homolog 2, reduces glioblastoma progression through inflammatory process modulation: focus on canonical and non-canonical NF-kappaB\/IkappaBalpha pathways","volume":"23","author":"Scuderi","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118311_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102600","article-title":"Review: Targeting EZH2 in neuroblastoma","volume":"119","author":"Gao","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2025.118311_bib37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2025.118311_bib38","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/ncomms5177","article-title":"Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation","volume":"5","author":"Sashida","year":"2014","journal-title":"Nat. Commun."},{"issue":"51","key":"10.1016\/j.biopha.2025.118311_bib39","doi-asserted-by":"crossref","first-page":"85624","DOI":"10.18632\/oncotarget.12928","article-title":"Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2","volume":"7","author":"Christofides","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.biopha.2025.118311_bib40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1101\/gad.186411.111","article-title":"A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia","volume":"26","author":"Simon","year":"2012","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118311_bib41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1101\/gad.181800.111","article-title":"EZH2 couples pancreatic regeneration to neoplastic progression","volume":"26","author":"Mallen-St Clair","year":"2012","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.biopha.2025.118311_bib42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.biopha.2025.118311_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics14131448","article-title":"The role of biomarkers in hpv-positive head and neck squamous cell carcinoma: towards precision medicine","volume":"14","author":"Krsek","year":"2024","journal-title":"Diagnostics"},{"issue":"9","key":"10.1016\/j.biopha.2025.118311_bib44","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-21-4316","article-title":"Association of TP53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer","volume":"28","author":"Deneka","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.biopha.2025.118311_bib45","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.3390\/ijms13022331","article-title":"Epigenetic disregulation in oral cancer","volume":"13","author":"Mascolo","year":"2012","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118311_bib46","doi-asserted-by":"crossref","DOI":"10.3892\/or.2023.8599","article-title":"Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain\u2011of\u2011function and targeting therapy (Review).","volume":"50","author":"Li","year":"2023","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2025.118311_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.oraloncology.2015.11.022","article-title":"The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations","volume":"56","author":"Geiger","year":"2016","journal-title":"Oral. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118311_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","article-title":"Regulation of tumor angiogenesis by EZH2","volume":"18","author":"Lu","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hernandez Borrero","year":"2021","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118311_bib50","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1368-8375(99)00093-7","article-title":"Alterations of p53, pRb, cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas","volume":"36","author":"Koontongkaew","year":"2000","journal-title":"Oral. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118311_bib51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/path.1242","article-title":"Mutated p53 as a molecular marker for the diagnosis of head and neck cancer","volume":"198","author":"van Houten","year":"2002","journal-title":"J. Pathol."},{"key":"10.1016\/j.biopha.2025.118311_bib52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fonc.2018.00095","article-title":"CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma","volume":"8","author":"Chen","year":"2018","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118311_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cells6020013","article-title":"Activation of the EGF receptor by ligand binding and oncogenic mutations: the \"rotation model\"","volume":"6","author":"Purba","year":"2017","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.biopha.2025.118311_bib54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/mp.53.4.165","article-title":"Molecular pathogenesis of oral squamous carcinoma","volume":"53","author":"Williams","year":"2000","journal-title":"Mol. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib55","first-page":"9","article-title":"Epidermal growth factor receptor (EGFR) in oral squamous cell carcinomas: overexpression, localization and therapeutic implications","volume":"8","author":"Kuttan","year":"1997","journal-title":"Indian J. Dent. Res"},{"issue":"28","key":"10.1016\/j.biopha.2025.118311_bib56","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1038\/s41388-022-02375-x","article-title":"EZH2 endorses cell plasticity to non-small cell lung cancer cells facilitating mesenchymal to epithelial transition and tumour colonization","volume":"41","author":"Gallardo","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118311_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.oraloncology.2008.03.016","article-title":"High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas","volume":"45","author":"Kidani","year":"2009","journal-title":"Oral. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118311_bib58","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1111\/jcmm.14579","article-title":"EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells","volume":"23","author":"Zheng","year":"2019","journal-title":"J. Cell Mol. Med"},{"issue":"12","key":"10.1016\/j.biopha.2025.118311_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123707","article-title":"Aberrant epigenetic regulation in head and neck cancer due to distinct EZH2 overexpression and DNA hypermethylation","volume":"19","author":"Mochizuki","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118311_bib60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.oraloncology.2015.11.002","article-title":"EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity","volume":"52","author":"Chang","year":"2016","journal-title":"Oral. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118311_bib61","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1078-0432.CCR-16-2248","article-title":"STAT3\/HOTAIR signaling axis regulates HNSCC growth in an EZH2-dependent manner","volume":"24","author":"Sun","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"5746","key":"10.1016\/j.biopha.2025.118311_bib62","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1126\/science.1118947","article-title":"Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3","volume":"310","author":"Cha","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.118311_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110773","article-title":"Interplay between EZH2\/beta-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets","volume":"109","author":"Milan","year":"2023","journal-title":"Cell Signal"},{"issue":"6","key":"10.1016\/j.biopha.2025.118311_bib64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","article-title":"The roles of EZH2 in cancer and its inhibitors","volume":"40","author":"Liu","year":"2023","journal-title":"Med Oncol."},{"key":"10.1016\/j.biopha.2025.118311_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216143","article-title":"EZH2 and NF-kappaB: a context-dependent crosstalk and transcriptional regulation in cancer","volume":"560","author":"Kaur","year":"2023","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.biopha.2025.118311_bib66","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41419-022-05169-x","article-title":"Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.118311_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/froh.2021.642238","article-title":"Inflammatory mediators in oral cancer: pathogenic mechanisms and diagnostic potential","volume":"2","author":"Niklander","year":"2021","journal-title":"Front Oral. Health"},{"issue":"3","key":"10.1016\/j.biopha.2025.118311_bib68","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.7314\/APJCP.2013.14.3.1681","article-title":"Tissue expression, serum and salivary levels of IL-10 in patients with head and neck squamous cell carcinoma","volume":"14","author":"Hamzavi","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"11","key":"10.1016\/j.biopha.2025.118311_bib69","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1158\/2326-6066.CIR-15-0017","article-title":"Neutrophils increase oral squamous cell carcinoma invasion through an invadopodia-dependent pathway","volume":"3","author":"Glogauer","year":"2015","journal-title":"Cancer Immunol. Res"},{"issue":"11","key":"10.1016\/j.biopha.2025.118311_bib70","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1940-6207.CAPR-11-0130","article-title":"EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia","volume":"4","author":"Cao","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.biopha.2025.118311_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115461","article-title":"Recent advances in EZH2-based dual inhibitors in the treatment of cancers","volume":"256","author":"Yang","year":"2023","journal-title":"Eur. J. Med Chem."},{"issue":"7","key":"10.1016\/j.biopha.2025.118311_bib72","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/aps.2017.7","article-title":"Structure of the PRC2 complex and application to drug discovery","volume":"38","author":"Shi","year":"2017","journal-title":"Acta Pharm. Sin."},{"issue":"12","key":"10.1016\/j.biopha.2025.118311_bib73","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1021\/ml3003346","article-title":"Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2","volume":"3","author":"Verma","year":"2012","journal-title":"ACS Med Chem. Lett."},{"issue":"12","key":"10.1016\/j.biopha.2025.118311_bib74","doi-asserted-by":"crossref","first-page":"8121","DOI":"10.1074\/jbc.M114.548651","article-title":"3-Deazaneplanocin A (DZNep), an inhibitor of S-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation","volume":"289","author":"Fujiwara","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.biopha.2025.118311_bib75","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nchembio0817-922b","article-title":"Erratum: the EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex","volume":"13","author":"He","year":"2017","journal-title":"Nat. Chem. Biol."},{"issue":"32","key":"10.1016\/j.biopha.2025.118311_bib76","doi-asserted-by":"crossref","first-page":"33720","DOI":"10.18632\/oncotarget.5606","article-title":"Targeting EZH2 regulates tumor growth and apoptosis through modulating mitochondria dependent cell-death pathway in HNSCC","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225005050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:57:52Z","timestamp":1754654272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225005050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":76,"alternative-id":["S0753332225005050"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118311","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting enhancer of zeste homolog 2: A novel therapeutic approach for head and neck cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118311"}}